Comparison of VerifyNow P2Y12 and thrombelastography for assessing clopidogrel response in stroke patients in China

详细信息    查看全文

• 作者：Hui-Hui Lv ; Shuai Wu ; Xu Liu ; Xiao-Li Yang ; Jian-Feng Xu…
• 关键词：VerifyNow P2Y12 ; Thrombelastography ; Clopidogrel low response ; Ischemic stroke
• 刊名：Neurological Sciences
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：37
• 期：2
• 页码：277-282
• 全文大小：439 KB
• 参考文献：1.European Stroke Organisation Executive C, Committee ESOW (2008) Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 25:457–507CrossRef
  2.Furie KL, Kasner SE, Adams RJ et al (2011) Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 42:227–276CrossRef PubMed
  3.Shuldiner AR, O’Connell JR, Bliden KP et al (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849–857PubMedCentral CrossRef PubMed
  4.Mega JL, Close SL, Wiviott SD et al (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354–362CrossRef PubMed
  5.Collet JP, Hulot JS, Pena A et al (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373:309–317CrossRef PubMed
  6.Cayla G, Hulot JS, O’Connor SA et al (2011) Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA 306:1765–1774CrossRef PubMed
  7.Gorog DA, Fuster V (2013) Platelet function tests in clinical cardiology: unfulfilled expectations. J Am Coll Cardiol 61:2115–2129CrossRef PubMed
  8.Price MJ, Endemann S, Gollapudi RR et al (2008) Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29:992–1000CrossRef PubMed
  9.Jeong YH, Kim IS, Choi BR et al (2008) The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow P2Y12 assay. Eur Heart J 29:2186–2187PubMedCentral CrossRef PubMed
  10.Geisler T, Zürn C, Simonenko R et al (2010) Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 31:59–66CrossRef PubMed
  11.Parodi G, Marcucci R, Valenti R et al (2011) High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 306:1215–1223CrossRef PubMed
  12.Bischof D, Dalbert S, Zollinger A et al (2010) Thrombelastography in the surgical patient. Minerva Anestesiol 76:131–137PubMed
  13.Tantry US, Bliden KP, Gurbel PA (2005) Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 46:1705–1709CrossRef PubMed
  14.Hobson AR, Petley GW, Dawkins KD et al (2007) A novel fifteen minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thrombelastography. Platelets 18:497–505CrossRef PubMed
  15.Madsen EH, Saw J, Kristensen SR et al (2010) Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, VerifyNow, and thrombelastography in patients undergoing percutaneous coronary intervention. Clin Chem 56:839–847CrossRef PubMed
  16.Sambu N, Hobson A, Curzen N (2011) “Short” thrombelastography as a test of platelet reactivity in response to antiplatelet therapy: validation and reproducibility. Platelets 22:210–216CrossRef PubMed
  17.Sternberg Z, Ching M, Sawyer RN et al (2013) Clopidogrel responsiveness in stroke patients on a chronic aspirin regimen. J Stroke Cerebrovasc Dis 22:725–732CrossRef PubMed
  18.Khanna V, Hobson A, Mikael R et al (2014) Does the VerifyNow P2Y12 assay overestimate “therapeutic response” to clopidogrel? Insights using short thrombelastography. Thromb Haemost 111:1150–1159CrossRef PubMed
  19.Carroll RC, Craft RM, Snider CC et al (2013) A comparison of VerifyNowR with PlateletMappingR–detected aspirin resistance and correlation with urinary thromboxane. Anesth Analg 116:282–286CrossRef PubMed
  20.Blais N, Pharand C, Lordkipanidzé M et al (2009) Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). Thromb Haemost 102:404–411PubMed
  21.Dichiara J, Bliden KP, Tantry US et al (2007) Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients. Platelets 18:414–423CrossRef PubMed
  22.Malinin A, Pokov A, Spergling M et al (2007) Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 119:277–284CrossRef PubMed
  23.Fox SC, Behan MWH, Heptinstall S (2004) Inhibition of ADP-induced intracellular Ca2 + responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1. Cell Calcium 35:39–46CrossRef PubMed
  24.Zhang HZ, Kim MH, Jeong YH (2014) Predictive values of post-clopidogrel platelet reactivity assessed by different platelet function tests on ischemic events in East Asian patients treated with PCI. Platelets 25:292–299CrossRef PubMed
  25.Breet NJ, van Werkum JW, Bouman HJ et al (2010) High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. J Thromb Haemost 8:2140–2148CrossRef PubMed
  26.Whiting D, DiNardo JA (2014) TEG and ROTEM: technology and clinical applications. Am J Hematol 89:228–232CrossRef PubMed
  27.Breet NJ, van Werkum JW, Bouman HJ et al (2010) Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303:754–762CrossRef PubMed
  28.Stone GW, Witzenbichler B, Weisz G et al (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382:614–623CrossRef PubMed
  29.Han Y, Lv HH, Liu X et al (2015) Influence of genetic polymorphisms on clopidogrel response and clinical outcomes in patients with acute ischemic stroke. CNS Neurosci Ther 21(9):692–697CrossRef PubMed
  
• 作者单位：Hui-Hui Lv (1)
  Shuai Wu (1)
  Xu Liu (2) (3)
  Xiao-Li Yang (1)
  Jian-Feng Xu (2) (3) (4)
  Yang-Tai Guan (6)
  Qiang Dong (5)
  S. Lilly Zheng (2) (3) (4)
  Jian-Ming Jiang (1)
  Shi-Xu Li (1)
  Zheng Luo (1)
  Li Li (1)
  Li-Xian An (1)
  Yan Han (1)
  
  1. Department of Neurology, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China
  2. State Key Laboratory of Genetic Engineering and Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, China
  3. Fudan Center for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, China
  4. Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, IL, USA
  6. Department of Neurology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
  5. Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Neurology
  Neuroradiology
  Neurosurgery
  Psychiatry
  
• 出版者：Springer Milan
• ISSN：1590-3478

文摘

Poor response to clopidogrel is often associated with recurrent ischemic events, and reliable platelet function tests are needed to identify clopidogrel low response (CLR). The aim of the study was to compare the consistency of VerifyNow P2Y12 and thrombelastography (TEG) in acute ischemic stroke patients treated with clopidogrel. Patients hospitalized in Changhai Hospital from August 2012 to September 2013 and assigned to treatment with a daily 75-mg dose of clopidogrel. The blood samples were taken on the 5–7th day to assess the capability of VerifyNow P2Y12 and TEG for evaluation of clopidogrel response, and all instrument parameters were used to perform correlation analysis. Patients with CLR were detected by using the methods and criteria published earlier (PRU ≥ 230 assayed by VerifyNow P2Y12 or TEG-Inhib% ≤30 % measured by TEG). Totally 58 patients were enrolled for the study and there were wide varieties in parameters of VerifyNow P2Y12 and TEG. Results showed a total of 17 and 9 patients, respectively, identified as CLR assessed by VerifyNow P2Y12 and TEG, but only three patients were detected to be clopidogrel low responders with both tests. The kappa consistency analysis showed poor consistency between VerifyNow P2Y12 and TEG results in terms of CLR (Kappa = −0.0349, p = 0.7730). Linear regression also demonstrated poor correlation between VerifyNow-PRU/VerifyNow-Inhib% and TEG-Inhib% (p = 0.07901 and p = 0.3788, respectively). Our study demonstrated that there was poor correlation between VerifyNow P2Y12 and TEG results, and VerifyNow P2Y12 showed a larger proportion of CLR than TEG. Keywords VerifyNow P2Y12 Thrombelastography Clopidogrel low response Ischemic stroke